trastuzumab

The drug is intended for the treatment of adult patients with HER2-positive breast cancer. It is used in early-stage cancer (neoadjuvant therapy before treatment or adjuvant therapy after it), as well as in metastatic or locally recurrent breast cancer in combination with docetaxel.

Form: solution for injection

ATC: L01FY01

Manufacturer: F. Hoffmann-La Roche Ltd

The drug is used for the treatment of adult patients with HER2-positive early breast cancer (both pre- and post-surgery), as well as for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer in combination with chemotherapy.

Form: solution for injection

ATC: L01FY01

Manufacturer: F. Hoffmann-La Roche Ltd

The drug is used for the treatment of breast cancer (at various stages) and metastatic gastric cancer or gastroesophageal junction cancer, provided there is HER2 protein overexpression in the tumor.

Form: lyophilisate for concentrate for infusion solution

ATC: L01FD01

Manufacturer: Genentech Inc. (Manufacturing of unpackaged products, primary packaging)

The drug is used to treat breast cancer (metastatic or early stage) and metastatic gastric cancer or gastroesophageal junction cancer, provided there is HER2 protein overexpression in the tumor.

Form: lyophilisate for concentrate for infusion solution

ATC: L01FD01

Manufacturer: F. Hoffmann-La Roche Ltd (secondary packaging, quality control testing, batch release; solvent (production of unpackaged product, primary packaging, secondary packaging, quality control testing, batch release))

The drug is used to treat adults with metastatic or early breast cancer if the tumor has a specific feature — overexpression of the HER2 protein or amplification of the HER2 gene.

Form: solution for injection

ATC: L01FD01

Manufacturer: F. Hoffmann-La Roche Ltd (manufacturing unpackaged products, packaging, quality control testing, batch release)

The drug is prescribed for the treatment of breast cancer (metastatic or early stage) and metastatic gastric or gastroesophageal junction cancer, provided the patient has HER2 protein overexpression.

Form: lyophilisate for concentrate for infusion solution

ATC: L01FD01

Manufacturer: PJSC Pharmaceutical Plant Egis (quality control, secondary packaging)

The drug is prescribed for the treatment of metastatic breast cancer (as monotherapy or in combination with other drugs), early-stage breast cancer, as well as metastatic gastric cancer or gastroesophageal junction cancer (in combination with other agents). In all cases, the presence of HER2 overexpression must be confirmed.

Form: lyophilisate for concentrate for infusion solution

ATC: L01FD01

Manufacturer: PJSC Pharmaceutical Plant Egis (medicinal product: quality control, secondary packaging)

The drug is prescribed to adult patients with HER2-positive metastatic breast cancer or early breast cancer. It is also used for the treatment of HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma in combination with other drugs.

Form: powder for concentrate for infusion solution

ATC: L01FD01

Manufacturer: Patheon Italia S.p.A. (manufacturing, primary packaging, quality control testing (sterility))

The drug is prescribed to adult patients with HER2-positive metastatic breast cancer or early breast cancer. It is also used to treat HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Form: powder for concentrate for infusion solution

ATC: L01FD01

Manufacturer: Fareva Paull (Manufacturing, primary packaging; quality control testing (bacterial endotoxins and sterility))

The drug is used for the treatment of adult patients with breast cancer (metastatic or early) and metastatic gastric cancer, if the tumors show overexpression or amplification of the HER2 gene.

Form: powder for concentrate for infusion solution

ATC: L01FD01

Manufacturer: Accord Healthcare Polska Sp. z o.o. Importer's Warehouse (Responsible for batch release)